Caroline Murphy

Dr. Caroline Murphy

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2018 in Diagnostics
Verified
Journal Article
Open access
PDF file
BHBryony Hayes
Bryony Hayes
CMCaroline Murphy
Caroline Murphy
ACAoife Crawley
Aoife Crawley
RORichard O'Kennedy
Richard O'Kennedy
Cancer is the cause of death for one in seven individuals worldwide. It is widely acknowledged that screening and early diagnosis are of vital importance for improving the likelihood of recovery. However, given the costly, time-consuming, and invasive nature of the many methods currently in use, patients often do not take advantage of the services available to them. Consequently, many researchers are exploring the possibility of developing fast, reliable, and non-invasive diagnostic tools that can be used directly or by local physicians at the point-of-care. Herein, we look at the use of established biomarkers in cancer therapy and investigate emerging biomarkers exhibiting future potential. The incorporation of these biomarkers into point-of-care devices could potentially reduce the strain currently experienced by screening programs in hospitals and healthcare systems. Results derived from point-of-care tests should be accurate, sensitive, and generated rapidly to assist in the selection of the best course of treatment for optimal patient care. Essentially, point-of-care diagnostics should enhance the well-being of patients and lead to a reduction in cancer-related deaths.

1 May 2015 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
CMCaroline Murphy
Caroline Murphy
ESEdwina Stack
Edwina Stack
SKSvetlana Krivelo
Svetlana Krivelo
DMDaniel A. McPartlin
Daniel A. McPartlin
BBBarry Byrne
Barry Byrne
RORichard J. O’kEnnedy
Richard J. O’kEnnedy

1 April 2017 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Open access
RORichard O'Kennedy
Richard O'Kennedy
SFSean Fitzgerald
Sean Fitzgerald
CMCaroline Murphy
Caroline Murphy

1 December 2018 in Journal of Immunological Methods
Verified
Journal Article
Closed access
CMCaroline Murphy
Caroline Murphy
ESEdwina Stack
Edwina Stack
SKSvetlana Krivelo
Svetlana Krivelo
MBMark Breheny
Mark Breheny
HMHui Ma
Hui Ma
RORichard O'Kennedy
Richard O'Kennedy

31 December 2019 in Protein Engineering, Design and Selection
Verified
Journal Article
Closed access
DMDaniel A McPartlin
Daniel A McPartlin
CMCaroline Murphy
Caroline Murphy
JFJenny Fitzgerald
Jenny Fitzgerald
HMHui Ma
Hui Ma
FRFiona Regan
Fiona Regan
RORichard J O’kEnnedy
Richard J O’kEnnedy
Microcystins (MCs) are a group of highly potent cyanotoxins that are becoming more widely distributed due to increased global temperatures and climate change. Microcystin-leucine-arginine (MC-LR) is the most potent and most common variant, with a guideline limit of 1 μg/l in drinking water. We previously developed a novel avian single-chain fragment variable (scFv), designated 2G1, for use in an optical-planar waveguide detection system for microcystin determination. This current work investigates interactions between 2G1 and MC-LR at the molecular level through modelling with an avian antibody template and molecular docking by AutoDock Vina to identify key amino acid (AA) residues involved. These potential AA interactions were investigated in vitro by targeted mutagenesis, specifically, by alanine scanning mutations. Glutamic acid (E) was found to play a critical role in the 2G1-MC-LR binding interaction, with the heavy chain glutamic acid (E) 102 (H-E102) forming direct bonds with the arginine (R) residue of MC-LR. In addition, alanine mutation of light chain residue aspartic acid 57 (L-D57) led to an improvement in antigen-binding observed using enzyme-linked immunosorbent assay (ELISA), and was confirmed by surface plasmon resonance (SPR). This work will contribute to improving the binding of recombinant anti-MC-LR to its antigen and aid in the development of a higher sensitivity harmful algal toxin diagnostic.

1 February 2017 in Advanced Health Care Technologies
Verified
Journal Article
Open access
PDF file
CMCaroline Murphy
Caroline Murphy
TDTatyana Devine
Tatyana Devine
RORichard O'Kennedy
Richard O'Kennedy
Technology advancements in antibody purification [Corrigendum] Murphy C, Devine T, Oâ